Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology.

Uchida T, Imamura M, Kan H, Hiraga N, Hayes CN, Tsuge M, Abe-Chayama H, Aikata H, Makokha GN, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K.

J Gen Virol. 2017 May;98(5):1040-1047. doi: 10.1099/jgv.0.000726. Epub 2017 May 25.

PMID:
28141486
2.

A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.

Kosaka K, Hiraga N, Imamura M, Yoshimi S, Murakami E, Nakahara T, Honda Y, Ono A, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Aikata H, Ochi H, Ishida Y, Tateno C, Yoshizato K, Sasaki T, Chayama K.

Biochem Biophys Res Commun. 2013 Nov 8;441(1):230-5. doi: 10.1016/j.bbrc.2013.10.040. Epub 2013 Oct 16.

PMID:
24140055
3.

Chimeric mouse model for the infection of hepatitis B and C viruses.

Tesfaye A, Stift J, Maric D, Cui Q, Dienes HP, Feinstone SM.

PLoS One. 2013 Oct 14;8(10):e77298. doi: 10.1371/journal.pone.0077298. eCollection 2013.

4.

Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice.

Vanwolleghem T, Libbrecht L, Hansen BE, Desombere I, Roskams T, Meuleman P, Leroux-Roels G.

J Hepatol. 2010 Sep;53(3):468-76. doi: 10.1016/j.jhep.2010.03.024. Epub 2010 May 31.

PMID:
20591528
5.

Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.

Klumpp K, Shimada T, Allweiss L, Volz T, Lütgehetmann M, Hartman G, Flores OA, Lam AM, Dandri M.

Gastroenterology. 2018 Feb;154(3):652-662.e8. doi: 10.1053/j.gastro.2017.10.017. Epub 2017 Oct 24.

PMID:
29079518
6.

The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.

Meuleman P, Leroux-Roels G.

Antiviral Res. 2008 Dec;80(3):231-8. doi: 10.1016/j.antiviral.2008.07.006. Epub 2008 Aug 14. Review.

PMID:
18706933
7.
8.

Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.

Lütgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok JM, Lohse AW, Petersen J, Urban S, Dandri M.

Hepatology. 2012 Mar;55(3):685-94. doi: 10.1002/hep.24758. Epub 2012 Jan 30.

PMID:
22031488
9.

Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera.

Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, Roskams T, Leroux-Roels G.

Hepatology. 2005 Apr;41(4):847-56.

PMID:
15791625
10.

Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice.

Tateno C, Kawase Y, Tobita Y, Hamamura S, Ohshita H, Yokomichi H, Sanada H, Kakuni M, Shiota A, Kojima Y, Ishida Y, Shitara H, Wada NA, Tateishi H, Sudoh M, Nagatsuka S, Jishage K, Kohara M.

PLoS One. 2015 Nov 4;10(11):e0142145. doi: 10.1371/journal.pone.0142145. eCollection 2015.

11.

Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.

Vanwolleghem T, Meuleman P, Libbrecht L, Roskams T, De Vos R, Leroux-Roels G.

Gastroenterology. 2007 Oct;133(4):1144-55. Epub 2007 Jul 10.

PMID:
17919490
12.

Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver disease.

Douglas DN, Kawahara T, Sis B, Bond D, Fischer KP, Tyrrell DL, Lewis JT, Kneteman NM.

PLoS One. 2010 Feb 18;5(2):e9209. doi: 10.1371/journal.pone.0009209.

13.

Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection.

Meuleman P, Steyaert S, Libbrecht L, Couvent S, Van Houtte F, Clinckspoor F, de Hemptinne B, Roskams T, Vanlandschoot P, Leroux-Roels G.

Clin Chim Acta. 2006 Apr;366(1-2):156-62. Epub 2005 Oct 25.

PMID:
16253217
14.

Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics.

Ishida Y, Chung TL, Imamura M, Hiraga N, Sen S, Yokomichi H, Tateno C, Canini L, Perelson AS, Uprichard SL, Dahari H, Chayama K.

Hepatology. 2018 Aug;68(2):473-484. doi: 10.1002/hep.29891. Epub 2018 Jun 6.

15.

Animal model for study of human hepatitis viruses.

Chayama K, Hayes CN, Hiraga N, Abe H, Tsuge M, Imamura M.

J Gastroenterol Hepatol. 2011 Jan;26(1):13-8. doi: 10.1111/j.1440-1746.2010.06470.x. Review.

PMID:
21175788
16.

Strong antiviral activity of the new l-hydroxycytidine derivative, l-Hyd4FC, in HBV-infected human chimeric uPA/SCID mice.

Volz T, Lütgehetmann M, Allweiss L, Warlich M, Bierwolf J, Pollok JM, Petersen J, Matthes E, Dandri M.

Antivir Ther. 2012;17(4):623-31. doi: 10.3851/IMP2075. Epub 2012 Feb 27.

PMID:
22368233
17.

Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes.

Sugiyama M, Tanaka Y, Kurbanov F, Maruyama I, Shimada T, Takahashi S, Shirai T, Hino K, Sakaida I, Mizokami M.

Gastroenterology. 2009 Feb;136(2):652-62.e3. doi: 10.1053/j.gastro.2008.10.048. Epub 2008 Oct 29.

PMID:
19041311
18.

Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus.

Meuleman P, Libbrecht L, Wieland S, De Vos R, Habib N, Kramvis A, Roskams T, Leroux-Roels G.

J Virol. 2006 Mar;80(6):2797-807.

19.

Development of humanized mice for the study of hepatitis C virus infection.

Turrini P, Sasso R, Germoni S, Marcucci I, Celluci A, Di Marco A, Marra E, Paonessa G, Eutropi A, Laufer R, Migliaccio G, Padron J.

Transplant Proc. 2006 May;38(4):1181-4.

PMID:
16757300
20.

Property of hepatitis B virus replication in Tupaia belangeri hepatocytes.

Sanada T, Tsukiyama-Kohara K, Yamamoto N, Ezzikouri S, Benjelloun S, Murakami S, Tanaka Y, Tateno C, Kohara M.

Biochem Biophys Res Commun. 2016 Jan 8;469(2):229-35. doi: 10.1016/j.bbrc.2015.11.121. Epub 2015 Nov 30.

Supplemental Content

Support Center